Hotspot Therapeutics CEO and leadership

A trained chemist, biotech entrepreneur and specialist in startup operations and business development, Jonathan's unique perspective aligns business and science interests. Inspired by the ability to translate lab-bench innovation into meaningful therapies for patients, Jonathan is driven to lead HotSpot to solve problems that the industry has grappled with for decades.

Prior to co-founding HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics, where he helped establish the company's drug discovery platform and pipeline. He also served as Vice President, Business Development at Concert Pharmaceuticals (CNCE), and was instrumental in securing a $1 B multi-product transaction for the company with GSK. Jonathan is currently an Entrepreneur-in-Residence at Atlas Venture.

Jonathan trained as a chemist at Oxford University, Cold Spring Harbor Laboratory, The Scripps Research Institute, and Cancer Research UK.

Working for more than 20 years in drug discovery & early development, Gerry's strong experience allows her to move seamlessly from one area of science to another, guiding cross-disciplinary problem solving. Drawn to medicine at an early age, she was fascinated to learn how the body works at its most basic level. This, together with her love of innovation, chemistry and biology culminated into a desire to discover new medicines.

Prior to co-founding HotSpot, Gerry served as Vice President and Head of ACC Program at Nimbus Therapeutics, where she led the effort to discover a leading drug for NASH. She also served as Vice President at Galenea, co-led the Inflammation Therapeutic Area at Millennium Pharmaceuticals, and was a founding member of the scientific team at LeukoSite.

Gerry received her Ph.D. in Chemistry at the University of Rhode Island and completed her post-doc fellowship at The University of Kansas.

Ms. Jack, a proven leader in the biopharmaceutical industry, brings a broad scope of business and operational experience to HotSpot Therapeutics. She has a highly successful track record in leading financings, forming and negotiating strategic collaborations, facilitating strategy development, and building and leading business, finance and other administrative functions.

She joined the team from Mersana Therapeutics, where she was the Chief Business Officer and played a major role in transforming the company from an early-stage start-up to a publicly traded, clinical-stage organization. She has also consulted with biotech companies and investors on business and financing strategies. Previously, she served as the Chief Business Officer of Pulmatrix, and before that, she was with Medlmmune (acquired by AstraZeneca). While at Medlmmune Ms. Jack was Managing Director of Medlmmune Ventures, where she was responsible for making and managing investments in private biotechnology companies. Prior to Medlmmune Ventures, she was in Medlmmune's Business Development group, where she was responsible for in- licensing, out-licensing and research collaborations. Prior to joining Medlmmune, Ms. Jack held a variety of positions at Intel Corporation, where she worked in venture investments, corporate strategy and public policy.

Ms. Jack holds a bachelor's degree from the University of Virginia and a master's degree in health sciences from The Johns Hopkins University. Additionally, she is a volunteer puppy raiser for Canine Companions for Independence@, a non- profit organization that enhances the lives of people with disabilities by providing highly trained assistance dogs.

Tim Reilly is a Chief Development Officer at HotSpot Therapeutics Inc.

A trained chemist, biotech entrepreneur and specialist in startup operations and business development, Jonathan's unique perspective aligns business and science interests. Inspired by the ability to translate lab-bench innovation into meaningful therapies for patients, Jonathan is driven to lead HotSpot to solve problems that the industry has grappled with for decades.

Prior to co-founding HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics, where he helped establish the company's drug discovery platform and pipeline. He also served as Vice President, Business Development at Concert Pharmaceuticals (CNCE), and was instrumental in securing a $1 B multi-product transaction for the company with GSK. Jonathan is currently an Entrepreneur-in-Residence at Atlas Venture.

Jonathan trained as a chemist at Oxford University, Cold Spring Harbor Laboratory, The Scripps Research Institute, and Cancer Research UK.

Working for more than 20 years in drug discovery & early development, Gerry's strong experience allows her to move seamlessly from one area of science to another, guiding cross-disciplinary problem solving. Drawn to medicine at an early age, she was fascinated to learn how the body works at its most basic level. This, together with her love of innovation, chemistry and biology culminated into a desire to discover new medicines.

Prior to co-founding HotSpot, Gerry served as Vice President and Head of ACC Program at Nimbus Therapeutics, where she led the effort to discover a leading drug for NASH. She also served as Vice President at Galenea, co-led the Inflammation Therapeutic Area at Millennium Pharmaceuticals, and was a founding member of the scientific team at LeukoSite.

Gerry received her Ph.D. in Chemistry at the University of Rhode Island and completed her post-doc fellowship at The University of Kansas.

A trained chemist, biotech entrepreneur and specialist in startup operations and business development, Jonathan's unique perspective aligns business and science interests. Inspired by the ability to translate lab-bench innovation into meaningful therapies for patients, Jonathan is driven to lead HotSpot to solve problems that the industry has grappled with for decades.

Prior to co-founding HotSpot, Jonathan served as Chief Business Officer at Nimbus Therapeutics, where he helped establish the company's drug discovery platform and pipeline. He also served as Vice President, Business Development at Concert Pharmaceuticals (CNCE), and was instrumental in securing a $1 B multi-product transaction for the company with GSK. Jonathan is currently an Entrepreneur-in-Residence at Atlas Venture.

Jonathan trained as a chemist at Oxford University, Cold Spring Harbor Laboratory, The Scripps Research Institute, and Cancer Research UK.